Lipocine (LPCN)Director bought ~$27K

~$27K

Approx. value · 13K sh @ $2.16

216K

Holds after · shares reported

Traded

Sep 28, 2026

Filed

Oct 1, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 3, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.”
2. Aug 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 18, 2026, the Board of Directors (the “Board”) of the Company appointed Michael Grissinger to serve as a member of the Compensation Committee of the Board.”
3. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
4. Sep 28, 2026 · this disclosureInsiderDirector purchased ~$27K of LPCN shares in the open market

What came next

1. Sep 29, 2026InsiderDirector purchased ~$19K of LPCN shares in the open market
2. Sep 30, 2026InsiderDirector purchased ~$36K of LPCN shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lipocine

For Lipocine, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LPCN page.

Other recent filings by John W. Higuchi, Director

• SEC Form 4 at Lipocine (LPCN)Oct 2, 2026
• SEC Form 4 at Lipocine (LPCN)Oct 2, 2026
• SEC Form 4 at Lipocine (LPCN)Apr 7, 2026
• SEC Form 4 at Lipocine (LPCN)Apr 6, 2026

The full history of John W. Higuchi, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Lipocine

• SEC Form 4Oct 2, 2026
• SEC Form 4Oct 2, 2026
• SEC Form 4Apr 7, 2026
• SEC Form 4Apr 6, 2026
• SEC Form 4Apr 6, 2026
• SEC Form 4Apr 2, 2026

Everything OQRO holds on this company is on its LPCN page.